Ingevity (NGVT)
(Delayed Data from NYSE)
$41.92 USD
-0.08 (-0.19%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $41.94 +0.02 (0.05%) 4:50 PM ET
2-Buy of 5 2
A Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.92 USD
-0.08 (-0.19%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $41.94 +0.02 (0.05%) 4:50 PM ET
2-Buy of 5 2
A Value B Growth F Momentum C VGM
Zacks News
Valvoline (VVV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Valvoline (VVV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ingevity's (NGVT) Earnings and Sales Beat Estimates in Q1
by Zacks Equity Research
Ingevity (NGVT) benefits from higher demand across its businesses in the first quarter.
Ingevity (NGVT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 18.69% and 9.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Ingevity (NGVT) Adds Caprolactone Polyol Production at DeRidder
by Zacks Equity Research
Ingevity's (NGVT) latest addition to production capabilities will enable it to cater to increasing demand for Capa suite of technologies.
Ingevity (NGVT) Expands Production Capacity at Zhuhai Plant
by Zacks Equity Research
Ingevity's (NGVT) plant upgrades help increase its capacity and enable it to serve global demand for premium carbon products.
Ingevity's (NGVT) Earnings and Sales Top Estimates in Q4
by Zacks Equity Research
Ingevity (NGVT) benefits from higher demand for engineered polymers and a recovery of global automotive production in Q4.
Ingevity (NGVT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 95.59% and 16.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ingevity (NGVT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ingevity (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity's (NGVT) Shares Gain 27% in 6 Months: Here's Why
by Zacks Equity Research
Ingevity (NGVT) gains on regulation-driven adoption of its applications and cost-cutting actions.
Ingevity (NGVT) Stock Up 15% in 3 Months: What's Driving It?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost actions, Capa acquisition and growth in its applications driven by regulations and technology adoption.
Venator (VNTR) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Venator (VNTR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
4 Chemical Specialty Stocks to Escape Industry Challenges
by Anindya Barman
Soft demand amid sluggish industrial activities due to coronavirus clouds prospects for the Zacks Chemicals Specialty industry. Quaker Chemical (KWR), Valvoline (VVV), Element Solutions (ESI) and Ingevity (NGVT) are set to gain from self-help actions.
Ingevity (NGVT) Up 12% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Should Add Ingevity (NGVT) Stock to Your Portfolio
by Zacks Equity Research
Ingevity (NGVT) benefits from regulation-driven adoption of its applications and cost-reduction measures.
Ingevity (NGVT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 82.65% and 6.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ingevity (NGVT) Up 44% in 6 Months: What's Behind the Rally?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost-management actions and regulation-driven demand for its applications.
Ingevity Gains on Cost Actions Amid Weak Industrial Demand
by Anindya Barman
Ingevity (NGVT) benefits from cost-reduction measures and growth in its applications driven by regulations and technology adoption.
Why You Should Keep Ingevity (NGVT) Stock in Your Portfolio
by Zacks Equity Research
While Ingevity (NGVT) faces headwind from soft demand in industrial specialties and oilfield technologies, it should gain from cost actions and regulation-driven adoption of its applications.
Ingevity (NGVT) Up 57% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost-saving actions and growth in its applications driven by regulations and technology adoption.
Why Is Ingevity Corporation (NGVT) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Ingevity (NGVT) Stock for Now
by Zacks Equity Research
While Ingevity (NGVT) is exposed to weakness in industrial specialties and oilfield technologies businesses, it should gain from strong demand for activated carbon products in China and cost actions.
Ingevity (NGVT) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Ingevity's (NGVT) Q2 revenues decline year over year on account of weaker demand, fuelled by the economic impacts of the coronavirus pandemic.
Ingevity Corporation (NGVT) Matches Q2 Earnings Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 0.00% and 7.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ingevity Corporation (NGVT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemical Specialty Industry Outlook Bleak on Muted Demand
by Anindya Barman
Weak demand and raw material supply disruptions due to coronavirus pose as headwinds to the chemical specialty industry.